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Abstract
The in vitro and in vivo bioactivities of silibinin (SB), paclitaxel (PTX) and SB and PTX in combination (SB+PTX) 
against murine metastatic mammary 4T1 cancer cell line were investigated. Isobologram and combination index (CI) 
analyses showed that SB and PTX can function synergistically in the inhibition of 4T1 cell proliferation with a CI 
value < 1. Both SB and PTX alone or SB+PTX treatment inhibited 4T1 cell migration and motility possibly through 
downregulation of the serpin protease nexin-1 (PN-1) and N-cadherin expression, inhibition of matrix metalloprotease 
(MMP)-9 activity, and upregulation of E-cadherin. Flow cytometry and Western blot analyses demonstrated that 
both drugs deregulated cell-cycle mediators and induced apoptosis in 4T1 cells. A real-time in vivo bioluminescence 
imaging system to monitor the breast cancer cell metastasis in syngeneic BALB/c mice was established using a stable 
4T1pGL-COX-2/Luc cell clone carrying a COX-2 promoter driven-luciferase reporter gene. In vivo study using the allograft 
4T1pGL-COX-2/Luc metastatic mouse model indicated that SB co-treated with PTX can significantly suppress lung metastasis 
of 4T1 cells likely through inhibiting cell proliferation and angiogenesis. Together, this study demonstrates that SB 
could act synergistically with PTX in 4T1 cells, providing a therapeutic option for highly metastatic triple negative 
breast cancer.
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Introduction
Breast cancer is the most common cancer in women, 
and the incidence, morbidity and mortality of the disease 
remain a major concern globally (Maxmen 2012). 
Immunohistochemical markers such as the expression 
of hormone receptors, e.g. , estrogen receptor (ER) and 
progesterone receptors (PR) and the overexpression of 
HER2, provide therapeutic predictive value and clinical 
guidance in selection of breast cancer treatments. 
While effective targeted therapeutic modalities exist 
for women with hormone receptor positive and HER2-
positive disease, chemotherapy is the only systemic 
therapy available for women with triple negative breast 
cancer (TNBC) (Lin et al., 2012). 
Chemotherapy is used extensively in treating cancers, 
but its effectiveness, drug resistance and adverse side 
This is an open access article under the CC BY-NC-ND license.
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effects in patients are common concerns. For instance, 
the side effects of a commonly used anticancer drug 
paclitaxel (PTX) include pain, hair loss, diarrhea, 
nausea, vomiting and lowered white blood and red 
blood cell counts with increased risk of infection and 
anemia in patients (Salvinelli et al ., 2003; Lee et al ., 
2012). This has led to the search for adjuvant therapy 
combining cytotoxic chemotherapeutic drugs with less 
toxic agent(s) with the potential to boost antitumor 
activity and reduce side effects that are considered to be 
an alternative approach for cancer treatment (Lin et al., 
2012; Sarkar & Li 2006). 
Silibinin (SB), the most active flavonolignan 
constituent present in the milk thistle (Silybum 
marianum  L.) extract silymarin has demonstrated 
pleiotropic effects against a variety of cancers (Deep 
& Agarwal 2010). Silymarin was reported previously 
for its clinical properties in the management of hepatic 
disorders (Wellington & Jarvis 2001). Preclinical studies 
indicate that SB or silymarin are also effective against 
epithelial-type cancers, such as prostate, lung, ovarian, 
colon, and skin cancers (Colombo et al ., 2011; Kaur 
& Agarwal 2007; Zhou et al ., 2008). SB or silymarin 
has thus been considered a novel candidate for cancer 
chemotherapy and chemoprevention as it is well 
tolerated and is considered safe (Hoh et al., 2006), and 
can enhance chemosensitivity to select anticancer drugs, 
e.g. , 5-fluorouracil, doxorubicin or PTX (Colombo et 
al., 2011; Zhou et al., 2008).
In the present study, we investigated the therapeutic 
effect and underlying mechanisms of SB, PTX and SB 
PTX cotreatment on triple negative breast cancer cells 
4T1 in vitro  and in an experimental lung metastatic 
mouse model. Our results demonstrate that SB and PTX 
can act synergistically by suppressing 4T1 cell activity 
through inhibiting migration, modulating cell-cycle 
machinery and inducing apoptosis. Both drugs also 
suppressed lung metastasis of 4T1 cells in syngeneic 
BALB/c mice.
Materials and Methods
Cell lines and culture conditions
The 4T1 murine metastatic breast cancer cell line was 
obtained from the American Type Culture Collection 
(ATCC, CRL-2539; Manassas, VA, USA). The TS/A 
murine adenocarcinoma cell line was a gift from Dr. 
Ning-Sun Yang of the Agriculture Biotechnology 
Research Center, Academia Sinica, Taiwan. The human 
normal breast epithelial cell line H184B5F5/M10 
(BCRC 60197) was purchased from the Bioresource 
Collection and Research Center (BCRC, Hsinchu, 
Taiwan). All cell lines were cultured in indicated media 
supplemented with 10% fetal bovine serum (FBS) and 
penicillin-streptomycin (Invitrogen, Carlsbad, CA, 
USA) in a humidified 5% CO2 incubator at 37°C.
Animals
All animal care and experimental procedures adhered 
to the guidelines of Academia Sinica Institutional 
Animal Care and Utilization Committee. Female 
BALB/cByJNar1 mice (six-week-old) obtained from 
National Laboratory Animal Center, Taipei, Taiwan) 
were given a standard laboratory diet and distilled water 
ad libitum and kept on a 12 h light/dark cycle at 22 ± 
2°C in the Animal Facility of Agricultural Biotechnology 
Research Center, Academia Sinica.
Cell proliferation and cell cycle analyses
In cell proliferation assays, 4T1 cells were cultured 
in 96-well plates at 4 × 103 cells/well and allowed to 
adhere overnight. The cells were then treated for 24 h 
with 0.2% vehicle of dimethyl sulphoxide (DMSO) or 
indicated concentrations of silibinin (SB) and paclitaxel 
(PTX) (St. Louis, Mo, USA). Cell proliferation was 
measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT)-based colorimetric assay.
Analysis of cell cycle was carried out as described 
previously (Shyur et al ., 2004). 4T1 cells (2 × 105 
cells/mL) were synchronized by incubation in medium 
containing 1% FBS for 12 h. The low-serum (1% FBS) 
medium was then replaced by medium containing 10% 
FBS, and the 4T1 cells were treated with vehicle, SB, 
PTX, or SB+PTX for 6, 12, 24, and 48 h, respectively. 
Both adherent and floating cells were collected, washed 
with phosphate-buffered saline (PBS) and fixed with 
1 mL of ice-cold 70% ethanol overnight at 4°C. Cells 
were stained with 0.2 mg/mL propidium iodide in 
darkness for 30 min at room temperature and analyzed 
by flow cytometry (FACS Calibular, BD Biosciences, 
Bedford, MA, USA).
Western blotting
Western blot analysis was performed following 
procedures described previously (Chiang et al ., 2005). 
Protein content was measured by the Bradford method 
(Bio-Rad Laboratories, Hercules, CA, USA). Proteins 
were resolved by 5–20% gradient SDS-PAGE and then 
electrotransferred to polyvinylidene difluoride (PVDF) 
membrane (Immobilon, Millipore, Bedford, MA, USA). 
The blot was incubated in blocking buffer (3% skim 
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milk in TBS buffer) for 30 min, and then incubated with 
antibodies against cleaved caspase 3, cleaved PARP 
(Cell Signaling, MA, USA), E-cadherin (Millipore 
Corp, Bedford, MA,USA), and cyclin D2, cyclin 
E, cdk 1, cdk 2, cyclin A, cyclin B1, cleaved PARP, 
N-cadherin, and actin (Santa Cruz Biochemicals, Santa 
Cruz, CA, USA) overnight at 4°C. After incubation with 
the appropriate secondary anti-rabbit or anti-mouse IgG 
conjugated to horseradish peroxidase, the reactive bands 
were visualized using enhanced chemiluminescence 
reagents (Amersham, Arlington Heights, IL, USA).
Analysis of synergistic effect of drugs combination
Isobologram analysis was used to determine the 
effects of SB and PTX in combination on 4T1 cells 
according to the Chou-Talalay method (Chou 2010). 
MTT assays were performed in 96 wells. Compound 1 
(SB or PTX) was applied at a fixed concentration while 
compound 2 (PTX or SB, respectively) was applied at 
a range of concentrations in order to determine whether 
the effects were dose-dependent. The interaction of 
two compounds was quantified by determining the 
combination index (CI), according to the following 
classic isobologram equation: CI = (D)1/(Dx)1 + 
(D)2/(Dx)2., where Dx is the dose of one compound 
alone required to produce an effect, and (D)1 and 
(D)2 are the doses of compounds 1 (SB) and 2 (PTX), 
respectively, in combination that produces the same 
effect as the compound alone. From this analysis, the 
combined effects of the two drugs can be summarized 
as follows: CI = 1 indicates summation (additive and 
zero interaction); CI < 1 indicates synergism; and CI > 1 
indicates antagonism.
Wound healing assay
4T1 cells were cultured in a 24-well plate until they 
formed a confluent monolayer. A wound (width 2 mm) 
was then created with a standard 2 mm wide strip. The 
cells were treated with indicated concentrations of SB, 
PTX or SB+PTX at 37 °C for 24 h and images were 
then taken by inverted microscopy (Axiovert 200M, 
Zeiss, Jena, Germany) at 100x, magnification. The cell 
numbers that migrated into the denuded area were 
counted.
Effect on MMP-2 and MMP-9 activities
The activities of the matrix metalloproteinase 
(MMP)-2 and MMP-9 were analyzed using zymography. 
After drug treatments, the conditioned media were 
collected and mixed with non-reducing sample buffer, 
then subjected to SDS-PAGE with 8% polyacrylamide 
gels copolymerized with 1 mg/mL gelatin. Gels were 
rinsed in washing buffer (50 mM Tris–HCl, pH 7.5, 
2.5% Triton X-100) at room temperature for 1 h and 
incubated overnight at 37°C in zymogram development 
buffer (50 mM Tris–HCl, pH 7.5, 10 mM CaCl2 and 150 
mM NaCl). Gels were fixed and stained with filtrated 
0.1% Coomassie brilliant blue R250. After destaining, 
gelatinolytic signals were quantified by densitometry. 
Gelatinolytic activities of MMP-2 and MMP-9 were 
visualized as a clear band appearing at 72 and 92 kDa, 
respectively, against a dark gel background.
Stable 4T1pGL-COX-2/Luc cell line generation
A stable 4T1 cancer cell clone carrying a COX-2 
promoter driven-luciferase (pGL-COX-2/Luc) reporter 
gene was established in this study. We previously 
constructed a gene plasmid in the pGL4.20-basic vector 
containing a luciferase reporter gene driven by the full 
length 5'  flanking promoter region (n1334/11) of the 
human COX-2 promoter (Hou et al., 2007). The plasmid 
was transfected into 4T1 cells using Lipofectamine 
PLUS (Invitrogen). Following several passages in the 
presence of puromycin (0.5 μg/mL), a stable 4T1 cell 
clone (designated 4T1pGL-COX-2/Luc) carrying the reporter 
gene and displaying the highest level of luciferase 
expression and activity among the selected transfected 
clones was isolated and used in the mouse lung 
metastasis experiments.
Effect on lung metastasis of 4T1 cells in BALB/c mice
The mouse tail vein was injected with 5 × 105 4T1 
COX-2/Luc cells on day 0. Mice were assigned to five 
groups (n = 6 per group) at day 1, including a vehicle 
control, a tumor control, and SB-200 (200mg/kg), 
PTX-2 (2mg/kg), PTX-5 (5mg/kg), and SB-200+PTX-2 
cotreatment groups. SB was fed by oral gavage and PTX 
was administered intraperitoneally (i.p.) every other day.
Prior to take the in vivo bioluminescence imaging, 
the mice were anesthetized with isoflurane (USP, 
South Carolina, USA) in an acrylic chamber with 2.5% 
isoflurane/air mixture and i.p.  injected with substrate 
D-luciferin solution (150 mg/kg) in PBS. After 10 
minutes, images were taken in the live anesthetized 
mice using a bioluminescence IVIS Spectrum System 
(Caliper, CA, USA), which includes a cryogenic cooling 
unit and a data acquisition computer running Living 
Image software (Xenogen Corp.). The acquisition 
and overlay of a pseudocolor image was taken that 
represented the spatial distribution of detected photons 
emerging from active luciferase within the animals. 
Bioluminescent signals were quantified using Living 
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Image 2.5 (Xenogen Corp.) as photons/sec/ROI (region 
of interest) at days 6, 10, 14 and 21 of treatment. 
At day 21, the experimental endpoints, luciferin-
injected animals were sacrificed, and lung organs were 
removed and imaged within 15 minutes of injection. The 
organs were then fixed with 10% buffered formalin and 
embedded in paraffin for haemotoxylin & eosin (H&E) 
staining and immunostaining with vascular endothelial 
growth factor (VEGF) and proliferating cell nuclear 
antigen (PCNA) antibody as described previously 
(Huang et al., 2010). 
Data analysis
All data are expressed as mean ± SEM. Differences 
between treatments were determined by unpaired, 
two-tailed Student’s t test or ANOVA. A P < 0.05 was 
considered statistically significant.
Results
Cytotoxic effect of silibinin and paclitaxel in breast 
cancer cells
The cytotoxic effect of silibinin (SB) (Figure. 1A) 
and paclitaxel (PTX) (Figure 1B) on ER(-) 4T1 and 
ER(+) TS/A murine mammary cancer cells were 
investigated. The test cells were exposed to a range of 
concentrations of SB (50-400 μM) or PTX (10-250 nM) 
for 24 h. SB was observed to induce a concentration-
dependent loss of cell viability with similar IC50 values 
in both 4T1 and TS/A cells as measured by MTT assay 
(Figure 1). The viability of normal mammary epithelial 
M10 cells tested in parallel was not affected by SB 
treatment at concentrations up to 400 μM (Figure 1C), 
which is in agreement with studies showing that SB is 
relatively safe in clinical applications. On the contrary, 
Figure 1. Inhibitory effect on breast cancer cell proliferation of silibinin and paclitaxel. (A-B) Chemical structures of silibinin (SB) and paclitaxel 
(PTX). Two murine breast cancer cell lines 4T1 (ER-) and TS/A (ER+) and normal mammary epithelial M10 cells were treated with indicated 
concentrations of SB (C) and PTX (D), respectively. Cell viability was determined by MTT assay.
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PTX induced more modest inhibition (60-67%) in the 
4T1 and TS/A cancer cell lines and in the normal M10 
cells at concentrations up to 250 nM (Figure 1D). These 
results indicate that the chemotherapeutic drug PTX 
did not discriminate between normal and cancer cells. 
We therefore proceeded to investigate whether SB 
can sensitize the cells or function synergistically with 
PTX against the triple negative breast cancer line 4T1; 
currently, no systemic clinical treatment protocol for 
TNBC yet exists.  
Combined effect of silibinin and paclitaxel on the 
growth of 4T1 cells
To investigate whether SB can act synergistically 
with PTX on 4T1 cell growth inhibition, cells were 
treated with SB and PTX alone or in combination for 
6 h, 12 h, and 24 h, respectively, and cell viability 
was assessed by MTT assay. The concentrations used 
were 150 μM SB (SB-150), 450 μM SB (SB-450), 
45 nM PTX (PTX-45), 180 nM PTX (PTX-180), and 
150 μM SB plus 45 nM PTX (SB-150/PTX-45).  We 
observed that the summation of percentage inhibition 
of SB-150 (14.9%) and PTX-45 (24.3%) was similar 
to that of SB-150/PTX-45 cotreatment (38.5%), 
and the combined treatment caused a significant 
(P  < 0.05) decrease in cytotoxicity in the 4T1 cells 
compared to SB-150 or PTX-45 (Figure 2A). We 
therefore performed isobologram analysis (Chou 
2010) to verify the combinational effect of SB and 
PTX against 4T1 cell activity.  The 4T1 cells were 
challenged with different concentration combinations 
of SB (50-350  μM) and PTX (20-150 nM) for 24 h 
to determine the combined concentrations which can 
reduce 40% cell viability (IC40). The combined effect 
of SB and PTX was then be evaluated by plotting the 
six concentration combinations, deriving a curve that 
connects the pairs of drug concentrations expected to 
induce 40% growth inhibition (IC40), and determining 
the relationship between this curve and the theoretical 
additive (dashed) line connecting the IC40 for SB (325 
μM) and the IC40 for PTX (125 nM) (Figure 2B). Our 
data produced a combination index (CI) < 1, indicating 
synergism of SB and PTX against 4T1 cells. Further, 
the range of CI values and combination inhibitory 
effects were calculated from the data obtained in Figure 
2B fell between 0.43 and 0.96, and 22.3% and 58.5%, 
respectively (Figure 2C). These results indicate that 
SB and PTX indeed acted synergistically to inhibit the 
growth of breast cancer cells.
Figure 2. Effects of silibinin and paclitaxel alone or in combination 
on the growth of 4T1 cells. (A) Percentage inhibition of 150 μM SB, 
450 μM SB, 45 nM PTX, 180 nM PTX, and 150 μM SB+45 nM PTX 
on 4T1 cell growth in different treatment times. Data are mean ± SD 
of three independent experiments. (B) Classic isobologram analysis 
of combined effect of SB and PTX producing 40% inhibition (IC40) 
in 4T1 cells. Cells (4000 cell/well) were treated with SB and PTX 
for 24 h. Values were the means of three independent experiments. 
The dashed line indicates the zero interaction of isobole. The CI <1 
indicates synergy; CI = 1 indicates an additive effect; and CI > 1 
indicates antagonism. (C) Combination index plot of SB and PTX co-
treatment.

Ho et al . / Journal of Traditional and Complementary Medicine 2 (2012) 
SB/PTX induces cell cycle perturbation and 
apoptosis
Flow cytometry analysis revealed that 12-h treatment 
decreased the G1 phase DNA content from 54.5% in the 
control group to 43.3% with SB-150 treatment, 32.7% 
with PTX-45 treatment, and 13.0% in cells treated with 
both SB-150 and PTX-45 (Figure 3A). Further, the G2/
M phase DNA content of the control group was 29.2%, 
and increased to 42.6% with SB-150 treatment, 45.2% 
with PTX-45 treatment, and 64.1% SB-150/PTX-45 
treatment. Apoptotic sub-G1 DNA was only identified 
in cells treated with PTX-45 and SB-150/PTX-45, with 
12.4% and 13.5%, respectively (Figure 3A). 
Next, we examined expression levels of key cell cycle 
mediators in synchronous 4T1 cells treated with SB and 
PTX (Figure 3B). Expression of the G1 phase mediators 
cyclin D2 and cyclin E decreased over the time course 
(6, 12, and 24 h) in 4T1 cells following treatment with 
SB-150, PTX-45, and SB-150/PTX-45. Expression 
of the G1/S phase mediator cdk2 slightly decreased in 
SB-150 and SB-150/PTX-45 treated cells, but remained 
unchanged in PTX-45 treated cells, compared to vehicle 
control cells. Cyclin A, involved in S and G2 phase 
transition, also decreased in all treatments groups. The 
Figure 3. Silibinin and paclitaxel induce cell-cycle arrest in 4T1 cells. (A) Flow cytometry analysis of DNA distribution in propidium iodide-stained 
cells. The 4T1 cells were treated with 0.2% DMSO (control), 150 μM SB (SB-150), 45 nM PTX (PTX-45) and 150 μM SB+45 nM PTX (SB-150/
PTX-45) for 12 h. The percentages of G1, S, G2/M, and sub-G1 cells were calculated. (B) Western blot analysis of protein expression levels of cell-
cycle mediators and apoptotic hallmark PARP. Western blot analysis of protein expression levels of cell-cycle mediators and apoptotic hallmark PARP 
in 4T1 cells treated with indicated concentrations and times of vehicle or drugs. Signal intensities of the band were determined by using the ImageJ 
software. Protein levels were normalized to the level of actin.
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expression of cyclin B1 and cdk1, proteins involved in 
the G2/M phase, increased over the time course in all 
treatments. Additionally cells receiving the combined 
SB-150/PTX-45 treatment also exhibited an increase in 
the cleaved form of PARP, a hallmark of apoptosis.
Effects of SB and PTX on metastatic activity of 4T1 
cells
The horizontal cell migration capacity of 4T1 cells 
was evaluated by wound healing assay as described 
previously (Huang et al ., 2010). Cells were treated 
with 0.2% DMSO (control), SB-150, SB-450, PTX-45, 
PTX-180 and SB-150/PTX-45 for 24 h, and the number 
of cells that had migrated into the wound (lesion) 
area was counted. The DMSO-treated control group 
had 702 ± 35 cells/field, while all treatment groups 
significantly inhibited cell migration (SB-150: 424 ± 
20 cells/field; SB-450: 218 ± 20 cells/field; PTX-45: 
201 ± 21 cells/field; PTX-180: 111 ± 17 cells/field; and 
SB-150/PTX-45: 141 ± 20 cells/field) (Figure 4A).     
Because of the significant effects induced by SB and 
PTX on cell migration, we next evaluated the effects of 
these drugs on MMP-2 and MMP-9 enzymatic activities 
in 4T1 cells using gelatin zymography. Little or no 
effect on MMP-2 activity was detected in the different 
treatment groups. However, cells treated with SB and 
PTX alone or together exhibited more reduced band 
intensities of MMP-9 relative to the control, indicating 
a reduction in MMP-9 activity (Vehicle: 1.0; SB-150: 
0.72; SB-45: 0.56; PTX-45: 0.85; PTX-180: 0.88; 
SB-150/PTX-45: 0.72) (Figure 4B). 
The expression of three other proteins involved in 
breast cancer cell motility, invasion and metastasis, 
i.e. , E-cadherin, N-cadherin and PN-1, were examined. 
Both drugs alone or in combination caused the increase 
of E-cadherin and the decrease of PN-1 protein 
expressions, but the decrease of N-cadherin protein 
observed in SB and SB/PTX treated cells were not 
observe in PTX treated cells (Figure 4C). 
Effect of SB and PTX on lung metastasis of 4T1 cells 
in BALB/c mice
To further investigate the influence of SB and PTX 
on 4T1 cancer cell metastasis in vivo, we established 
Figure 4. Silibinin and paclitaxel inhibit wound healing and MMP-9 activity in 4T1 cells. (A) Inhibitory effect on cell migration was assessed by 
wound healing assay. The effect on the movement of 4T1 cells into the denuded area by treatment with indicated concentrations of SB, PTX or 
SB+PTX at 37 ℃ for 24 h was quantified by counting the numbers of cells. (B) Zymography analysis of MMP-9 and MMP-2 activity in 4T1 cells. 
The gelatinolytic bands corresponding to MMP-9 and MMP-2 proteins are indicated. The ratios of active MMP-9 and MMP-2 bands relative to that in 
vehicle control were determined by densitometry. (C) Western blot analysis of E-cadherin, N-cadherin and PN-1 proteins in 4T1 cells with vehicle or 
drug treatments for 24 h. 
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Figure 5. Silibinin and paclitaxel inhibit lung metastasis of 4T1 cells in syngeneic BALB/c mice. (A) Bioluminescence imaging of lung organs 
of female BALB/c mice 21 days after 4T1pGL-COX-2/Luc cell implementation, and treatment with vehicle, 200 mg/kg SB (SB-200), 2 mg/kg PTX 
(PTX-2), 5 mg/kg PTX (PTX-5), and 200 mg/kg SB+2 mg/kg PTX (SB-200/PTX-2) SB. Fluorescent (Light emission) intensities of metastatic 
cancer cells in lung tissues were acquired using the IVIS Spectrum System (Xenogen Corp.). Quantification of photon counts representing degree 
of metastasis is shown. *: Significant difference with P < 0.05 as determined by one-way ANOVA. (B) Haemotoxylin and eosin (H&E) staining and 
immunohistochemical analysis.  The representative levels of vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (PCNA) 
in lung tissues of sham control, tumor control, 200 mg/kg SB (SB-200), 2 mg/kg PTX (PTX-2), 5 mg/kg PTX (PTX-5), and 200 mg/kg SB+2 mg/kg 
PTX (SB-200/PTX-2) treatment groups are shown. Scale bar = 200 μM.
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a stable 4T1pGL-COX-2/Luc cell line carrying a COX-2 
promoter-driven luciferase reporter gene for in situ 
and live monitoring of cancer cell migration and 
location in test animals. The 4T1pGL-COX-2/Luc cells were 
introduced by intravenous (i.v.) injection into BALB/c 
mice at mammary fat pad areas, and 21 days later 
bioluminescence imaging was performed to determine 
the degree of lung metastasis of the cancer cells in test 
animals (Figure 5A). Significant inhibition of 4T1 cell 
metastasis into the lungs was detected in all treatment 
groups, i.e. , PTX-2, PTX-5, SB-200, and SB-200/PTX-2 
compared to the tumor group (P < 0.05). However, no 
statistical difference was observed among the treatment 
groups (Figure 5A). 
The lung tissues from the mice were sectioned and 
subjected to pathological examination by H&E staining, 
or immunohistochemical analysis by antibodies against 
PCNA and VEGF. The percentage of cells positive for 
VEGF in the tumor group was 71.8 ± 2.9%, which was 
markedly higher than those detected in the SB-200 
(46.5 ± 2.6%), PTX-2 (22.5 ± 3.8%), PTX-5 (15.8 ± 
3.5%), and SB-200/PTX-2 (8.0 ± 1.1%) groups.  The 
differences within the tumor and treatment groups were 
all highly significant with P < 0.05 (one-way ANOVA). 
Similarly, the percentage of positive PCNA tumor cells 
in the untreated tumor group was 85.8 ± 1.9% which 
was greater than those detected in SB-200 (48.3 ±
5.2%), PTX-2 (60.5 ± 4.4%), PTX-5 (56.8 ± 4.0%), 
and SB-200/PTX-2 (25.5 ± 3.4%) groups (P  < 0.05, 
one-way ANOVA) (Figure 5B). Notably, SB and PTX 
co-treatment resulted in more substantial inhibition of 
both PCNA and VEGF expression, which is in good 
agreement with the in vitro data (Figure 2), suggesting 
synergism of SB and PTX on cancer cell activity. 
Discussion
The outcome of breast cancer treatment has improved 
steadily over the last fifty years. However, the cure rates 
are unlikely to be raised further with current therapies, 
especially for patients with metastatic breast cancer. 
Chemotherapeutic drugs, such as paclitaxel, are usually 
cytotoxic and pose adverse effects to patients. Moreover, 
paclitaxel can lead to development of drug resistance 
in tumor cells, thereby limiting the clinical success of 
general chemotherapies (Ribeiro et al ., 2012; Lee et 
al ., 2012). In an effort to develop effective alternative 
strategies that can increase the therapeutic efficacy while 
minimizing the systemic toxicity of chemotherapeutic 
agents, the use of phytoagents in combination with 
anticancer drugs may provide alternative and promising 
treatment options (Lee et al., 2012; Hsan et al., 2010). 
Medicinal herbs are a promising source of new lead 
compound discovery and future medicine development 
(Kinghorn et al., 2011; Koop 2002). More than 60% of 
new chemical entities approved between 1982 and 2006 
were from natural products or their derivatives (Cragg 
et al ., 2009). Silibinin (SB), the natural flavonolignan 
identified from the medicinal milk thistle plant is 
well-known for its hepatoprotective properties, and 
is also a potentially chemopreventive agent against 
various cancers by targeting proliferation, apoptosis, 
and metastasis (Deep & Agarwal 2010). Recent 
reports showed that SB could be used in combination 
with chemotherapeutics, e.g. , PTX, 5-fluorouracil or 
doxorubicin, to increase the chemosensitivity and lower 
the systemic toxicity of the anti-cancer drugs, or to 
synergistically inhibit tumor progression in vitro or in 
vivo of the ovarian carcinoma cells (Zhou et al., 2008), 
renal carcinoma cells (Chang et al., 2011), or multidrug-
resistant colon cancer cells (Colombo et al ., 2011). 
In the present study, we observed that SB inhibited 
proliferation of both 4T1 (ER-) and TS/A (ER+) breast 
cancer cell lines with a similar IC50 value (Figure 1). 
Aggressive and recurrent metastasis is often a hallmark 
of triple-negative breast cancers (TNBC), and specific 
treatment options are limited in these tumors (Foulkes 
et al ., 2010). We therefore used the triple negative 
4T1 breast cancer cell line derived from a syngeneic 
mouse that exhibits a similar aggressive phenotype to 
the human disease to assess the anticancer effects and 
modes of action of SB alone and in combination with 
PTX. We determined that co-treatment of SB and PTX 
exerted synergistic antiproliferative (Figure 2) and 
antimigratory (Figure 4) effects in vitro, suggesting SB 
enhanced chemosensitivity of 4T1 cells to PTX.
It has been revealed that aberrant activity of cell 
cycle protein kinases is a hallmark of hyperproliferative 
cancer cells. Cyclin dependent kinases, a family of 
serine/threonine kinases, regulate the transition from 
one cell cycle phase to another that are activated at 
specific checkpoint of the cell cycle (Vermeulen et al ., 
2003). In this study, we observed that antiproliferative 
effects of SB or in combination with PTX on 4T1 cells 
were possibly through modulating the activity of cyclin 
B1/cdk1 (responsible for G2/M transition), and cyclin 
E/cdk2 or cyclin A/cdk2 (G1/S mediators).
The poor clinical outcome of the vast majority of all 
cancers is mainly due to the invasion and metastasis of 
metastatic tumor cells and the outgrowth of secondary 
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tumors at distant sites. MMPs play crucial roles in the 
processes of invasion and metastasis and have been 
found to be of prognostic significance in breast cancers 
(Kohrmann et al ., 2009). In our studies, SB treatment 
only inhibited the expression of MMP-9 in a dose-
dependent manner (Figure 4B). Another metastasis-
associated protein, protease nexin 1 (PN-1), a serine 
protease inhibitor (serpin), has an expression profile that 
varies significantly between non-metastatic and highly 
metastatic breast cancer cells and has therefore been 
suggested to be a useful marker for the degree of tumor 
progression (Candia et al., 2006). The overexpression of 
PN-1 in 4T1 cells has also been previously reported for 
correlating directly to the increase of MMP-9 expression 
and enzymatic activity and to the lung metastatic 
behavior of 4T1 tumors (Fayard et al ., 2009). We thus 
propose that SB treatment results in deregulated PN-1 
expression, which then induces a decrease of MMP-9 
activity and ultimately a decrease in lung metastasis of 
4T1 cells (Figure 4 and 5). 
Several studies have shown a correlation between 
the action of E-cadherin and N-cadherin on tumor 
cell adhesion and migration. Specifically, E-cadherin 
functions as a suppressor of metastasis, and loss of 
E-cadherin correlates with advanced tumor grade 
and poor outcome in breast patients (Heimann et al ., 
2000; Oka et al ., 1993; Siitonen et al ., 1996). On 
the other hand, gain of N-cadherin action in breast 
cancer enhances cell motility and facilitates tumor 
cell interaction with host stromal cells (Nieman et al ., 
1999). Our results showing that treatment with SB 
alone or in combination with PTX resulted in increased 
E-cadherin expression and reduced N-cadherin 
expression (Figure 4C). It is known that the ratio of 
relative E-cadherin and N-cadherin protein level can 
refer to the degree of metastasis to be inhibited; when 
the ratio is higher the metastatic activity is inhibited 
greater. Based on the Western blotting data, we obtained 
that the relative E-cadherin/N-cadherin ratio in SB-150, 
SB-450, PTX-45, PTX-180, and SB-150/PTX-45 
treated cells were 1.91, 3.43, 0.54, 0.93, and 2.57, 
respectively, indicating the SB-150/PTX/45 cotreatment 
showed highest inhibition on 4T1 cell metastasis 
with synergism. This data maybe relatable to a 
mechanism for the inhibition of 4T1 cell migration 
and metastasis observed in vivo  by SB and PTX 
treatment. Additionally, we examined focal-adhesion 
kinase (FAK), a non-receptor tyrosine kinase acting as 
biosensors or integrator to control cell motility (Mitra 
et al ., 2005) and observed significantly decreased levels 
of both the unphosphorylated and phosphorylated forms 
in cells treated with SB-150/PTX-45 treatment (data not 
shown), suggesting the drug treatment attenuated cancer 
cell motility.
   To investigate the in vivo effects of SB alone and 
in combination with PTX, a metastatic 4T1pGL-COX-2/Luc 
cell clone containing COX-2 promoter-driven luciferase 
reporter gene was established and introduced into a 
syngeneic BALB/c mouse model. The lung metastasis of 
4T1pGL-COX-2/Luc cancer cells in mice was readily observed 
as examined by the IVIS imaging system. We observed 
the decrease of lung bioluminescence intensities in the 
SB, PTX and SB+PTX treatment groups, which were 
significantly lower than that of the tumor control group 
(P < 0.05), indicating the treatments can all effectively 
suppress 4T1 cells metastasized to the lungs in test 
mice. Furthermore, immunostaining of the lungs of 
mice that received SB and PTX together revealed more 
significantly reduction on the expression of PCNA and 
VEGF proteins than those found in mice treated with SB 
or PTX alone (Figure 5B). VEGF is a critical molecule 
involved in angiogenesis, an important process for 
tumor growth and metastasis. Our data suggest that SB 
in combination with PTX inhibited VEGF expression, 
which may then prevents angiogenesis in 4T1 tumor-
bearing mice. A similar mechanism has been previously 
described in colorectal cancer, where SB that was 
implicated in the deregulation of VEGF and inhibition 
of proliferation and angiogenesis (Singh et al., 2008). 
Despite some limitations in our study, data from 
MMP levels in vitro  (Figure 4B) and lung metastasis 
in vivo  (Figure 5A) were not synergy. Overall, 
combination of SB and PTX still have enough evidences 
to prove the synergistic effects on 4T1 model via the 
data of PN-1, the ratio of E-cadherin/N-cadherin (Figure 
4C), and immunohistochemical analysis of PCNA and 
VEGF (Figure 5B). 
Taken together, our data shows that SB synergistically 
cooperates with the toxic anti-cancer drug PTX to 
inhibit proliferation, migration, and motility of 4T1 cells 
in vitro  and to reduce metastatic efficacy in vivo, which 
provides a foundation for a novel therapeutic option in 
triple negative, highly metastatic breast tumor cells.
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